So far, only one study in adults with CKD has shown a benefit of adding FGF23 to existing prediction models for CKD progression (124), whereas all other studies have thus far failed to show any advantage in risk prediction for CKD onset when including FGF23 (125–127). The gene discussed is FGF23; the disease is chronic kidney disease.